405 related articles for article (PubMed ID: 31454256)
1. Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis.
McElvaney OJ; Zaslona Z; Becker-Flegler K; Palsson-McDermott EM; Boland F; Gunaratnam C; Gulbins E; O'Neill LA; Reeves EP; McElvaney NG
Am J Respir Crit Care Med; 2019 Dec; 200(11):1381-1391. PubMed ID: 31454256
[No Abstract] [Full Text] [Related]
2. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
Primiano MJ; Lefker BA; Bowman MR; Bree AG; Hubeau C; Bonin PD; Mangan M; Dower K; Monks BG; Cushing L; Wang S; Guzova J; Jiao A; Lin LL; Latz E; Hepworth D; Hall JP
J Immunol; 2016 Sep; 197(6):2421-33. PubMed ID: 27521339
[TBL] [Abstract][Full Text] [Related]
4. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
Krishnan SM; Ling YH; Huuskes BM; Ferens DM; Saini N; Chan CT; Diep H; Kett MM; Samuel CS; Kemp-Harper BK; Robertson AAB; Cooper MA; Peter K; Latz E; Mansell AS; Sobey CG; Drummond GR; Vinh A
Cardiovasc Res; 2019 Mar; 115(4):776-787. PubMed ID: 30357309
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of NLRP3 Inflammasome Prevents LPS-Induced Inflammatory Hyperalgesia in Mice: Contribution of NF-κB, Caspase-1/11, ASC, NOX, and NOS Isoforms.
Dolunay A; Senol SP; Temiz-Resitoglu M; Guden DS; Sari AN; Sahan-Firat S; Tunctan B
Inflammation; 2017 Apr; 40(2):366-386. PubMed ID: 27924425
[TBL] [Abstract][Full Text] [Related]
7. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
Qu J; Yuan Z; Wang G; Wang X; Li K
Int Immunopharmacol; 2019 May; 70():147-155. PubMed ID: 30802677
[TBL] [Abstract][Full Text] [Related]
8. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model.
Zhang W; Ba G; Tang R; Li M; Lin H
Int Immunopharmacol; 2020 Jun; 83():106394. PubMed ID: 32193102
[TBL] [Abstract][Full Text] [Related]
9. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.
Gao R; Shi H; Chang S; Gao Y; Li X; Lv C; Yang H; Xiang H; Yang J; Xu L; Tang Y
Int Immunopharmacol; 2019 Sep; 74():105575. PubMed ID: 31299609
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
[TBL] [Abstract][Full Text] [Related]
11. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation.
Yaw ACK; Chan EWL; Yap JKY; Mai CW
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2219-2229. PubMed ID: 32507974
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
[TBL] [Abstract][Full Text] [Related]
13. Nlrp3 Inflammasome Inhibitor MCC950 Ameliorates Obliterative Bronchiolitis by Inhibiting Th1/Th17 Response and Promoting Treg Response After Orthotopic Tracheal Transplantation in Mice.
Xu KY; Tong S; Wu CY; Ding XC; Chen JL; Ming Y; Wang SH
Transplantation; 2020 Jun; 104(6):e151-e163. PubMed ID: 32108749
[TBL] [Abstract][Full Text] [Related]
14. An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice.
Ludwig-Portugall I; Bartok E; Dhana E; Evers BD; Primiano MJ; Hall JP; Franklin BS; Knolle PA; Hornung V; Hartmann G; Boor P; Latz E; Kurts C
Kidney Int; 2016 Sep; 90(3):525-39. PubMed ID: 27262364
[TBL] [Abstract][Full Text] [Related]
15. The covalent NLRP3-inflammasome inhibitor Oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice.
Gao RF; Li X; Xiang HY; Yang H; Lv CY; Sun XL; Chen HZ; Gao Y; Yang JS; Luo W; Yang YQ; Tang YH
Int Immunopharmacol; 2021 Jan; 90():107133. PubMed ID: 33168408
[TBL] [Abstract][Full Text] [Related]
16. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
[TBL] [Abstract][Full Text] [Related]
17. MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants.
Schuh E; Groß CJ; Wagner D; Schlüter M; Groß O; Kümpfel T
Clin Immunol; 2019 Jun; 203():45-52. PubMed ID: 30974290
[TBL] [Abstract][Full Text] [Related]
18. Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis.
Gabillard-Lefort C; Casey M; Glasgow AMA; Boland F; Kerr O; Marron E; Lyons AM; Gunaratnam C; McElvaney NG; Reeves EP
Am J Respir Crit Care Med; 2022 Apr; 205(7):783-794. PubMed ID: 35021019
[No Abstract] [Full Text] [Related]
19. Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model.
Sui A; Chen X; Shen J; Demetriades AM; Yao Y; Yao Y; Zhu Y; Shen X; Xie B
Cell Death Dis; 2020 Oct; 11(10):901. PubMed ID: 33093455
[TBL] [Abstract][Full Text] [Related]
20. Evidence against a role for NLRP3-driven islet inflammation in db/db mice.
Kammoun HL; Allen TL; Henstridge DC; Barre S; Coll RC; Lancaster GI; Cron L; Reibe S; Chan JY; Bensellam M; Laybutt DR; Butler MS; Robertson AAB; O'Neill LA; Cooper MA; Febbraio MA
Mol Metab; 2018 Apr; 10():66-73. PubMed ID: 29478918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]